Clinical Trials Browser

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT03121599 2020-08-11

18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Phase NA Terminated

3 enrolled

Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT03669965 2020-07-31

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Phase 2 Unknown

20 enrolled

Myeloid

Polycythemia Vera

NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Phase 2 Terminated

39 enrolled

Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Phase 1/2 Completed

50 enrolled 23 charts

Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT00606307 2019-12-03

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Phase 2 Completed

29 enrolled 8 charts

Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00928707 2019-10-31

PV

Phase 2 Completed

45 enrolled 10 charts

Myeloid

Polycythemia Vera

NCT01901432 2019-07-30

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Phase 1/2 Completed

48 enrolled 28 charts

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT02292446 2019-07-18

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Phase 3 Completed

161 enrolled 14 charts

Myeloid

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT01243944 2019-03-06

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Phase 3 Completed

222 enrolled 21 charts

Myeloid

Polycythemia Vera

Clinical Trials

CINC424A2X01B Rollover Protocol

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

MK-3543-017

GIV-IN-PV

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

ROPE

SLN

Managed Access Programs for INC424, Ruxolitinib

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Prospero

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

A Study of GLB-001 in Patients With Myeloid Malignancies

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

VERIFY

THRIVE

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

PV

MK-3543-004

Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)

A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

A Study to Evaluate P1101 in Japanese PV Patients

PAVE

PACIFIC

Safety Evaluation Study for Patients With Polycythemia Vera

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

RESPONSE-2

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

Study of Select Combinations in Adults With Myelofibrosis

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

PV

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)